(NASDAQ: FENC) Fennec Pharmaceuticals's forecast annual revenue growth rate of 51.51% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Fennec Pharmaceuticals's revenue in 2025 is $30,912,000.On average, 2 Wall Street analysts forecast FENC's revenue for 2025 to be $1,347,242,284, with the lowest FENC revenue forecast at $1,270,185,991, and the highest FENC revenue forecast at $1,424,298,577. On average, 2 Wall Street analysts forecast FENC's revenue for 2026 to be $2,236,980,089, with the lowest FENC revenue forecast at $2,050,967,855, and the highest FENC revenue forecast at $2,422,992,323.
In 2027, FENC is forecast to generate $2,906,596,513 in revenue, with the lowest revenue forecast at $2,906,596,513 and the highest revenue forecast at $2,906,596,513.